Innoviva and GARDP reveal positive results for antibiotic to treat gonorrhoea
Zoliflodacin inhibits the vital bacterial enzyme for bacterial function and reproduction
Read More
Tag: Innoviva
US expands scope of Trelegy Ellipta to include asthma
Trelegy Ellipta is now the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US
Read More
EU expands label of GSK/Innoviva’s COPD inhaler
The European Commission expanded the scope of GlaxoSmithKline/Innoviva’s once-daily Trelegy Ellipta to reach more patients with COPD.
Read More
GSK/Innoviva’s Trelegy Ellipta wins expanded nod for COPD
US regulators have approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta to treat a wider population of chronic obstructive pulmonary disease (COPD) patients.
Read More
GSK, Innoviva seek to expand scope of Trelegy Ellipta
GlaxoSmithKline and Innoviva have submitted new data to regulators in the US in support of expanding the label of Trelegy Ellipta in chronic obstructive pulmonary disease.
Read More
GSK, Innoviva announce US nod for Trelegy Ellipta
GlaxoSmithKline and Innoviva have bagged a green light in the US for the novel triple therapy inhaler Trelegy Ellipta, opening the door to a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).
Read More
GSK’s inhaler improves asthma control in ‘real world’ study
GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
Read More
GSK files three-drug COPD inhaler in the US
GlaxoSmithKline and Innoviva have filed for approval in the US of a new once-daily, triple combination therapy for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), some 18 months earlier than originally planned.
Read More
GSK/Innoviva’s triple therapy hits targets in COPD trial
GlaxoSmithKline and Innoviva’s three-drug inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) has come out on top in a trial assessing its effectiveness against the dual therapy Symbicort Turbohaler in patients with chronic obstructive pulmonary disorder (COPD).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
